Hypersomnia: Evaluation, Treatment, and Social and Economic Aspects.
Most central disorders of hypersomnolence are conditions with poorly understood pathophysiologies, making their identification, treatment, and management challenging for sleep clinicians. The most challenging to diagnose and treat is idiopathic hypersomnia. There are no FDA-approved treatments, and off-label usage of narcolepsy treatments seldom provide benefit. Patients are largely left on their own to alleviate the compound effects of this disorder on their quality of life. This review covers the major points regarding clinical features and diagnosis of idiopathic hypersomnia, reviews current evidence supporting the available treatment options, and discusses the psychosocial impact and effects of idiopathic hypersomnia.
Department of Neurology, Emory University School of Medicine, 12 Executive Park Drive Northeast, Room 426, Atlanta, GA 30329, USA. Electronic address: Prabhjyot.saini@emory.edu.
Prabhjyot
P
Saini
Department of Neurology and Program in Sleep, Emory University School of Medicine, 12 Executive Park Drive Northeast, Room 427, Atlanta, GA 30329, USA.
David B
DB
Rye
D006970:Disorders of Excessive Somnolence / Q000175:diagnosis / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000009:adverse effects
D006993:Hypnotics and Sedatives
Economic costs; Excessive daytime sleepiness; Hypersomnolence disorder; Idiopathic hypersomnia; Narcolepsy; Psychosocial factors; Quality of life; Sleep drunkenness